PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,270 | +23.2% | 152,079 | +2.9% | 0.18% | +4.8% |
| Q1 2024 | $4,277 | +146.2% | 147,843 | +95.1% | 0.17% | +138.6% |
| Q4 2023 | $1,737 | +43.0% | 75,760 | +4.0% | 0.07% | +22.8% |
| Q3 2023 | $1,215 | +61.6% | 72,830 | +167.5% | 0.06% | +72.7% |
| Q2 2023 | $752 | +55.4% | 27,230 | +29.3% | 0.03% | +43.5% |
| Q1 2023 | $484 | -47.3% | 21,060 | -75.0% | 0.02% | -54.9% |
| Q4 2022 | $918 | -99.8% | 84,172 | +18.7% | 0.05% | +41.7% |
| Q3 2022 | $598,000 | -14.2% | 70,932 | -19.5% | 0.04% | -30.8% |
| Q2 2022 | $697,000 | +21.0% | 88,097 | +262.3% | 0.05% | +36.8% |
| Q1 2022 | $576,000 | +206.4% | 24,317 | +56.7% | 0.04% | -44.9% |
| Q2 2019 | $188,000 | +42.4% | 15,517 | +48.0% | 0.07% | -8.0% |
| Q1 2019 | $132,000 | +40.4% | 10,487 | -25.3% | 0.08% | +188.5% |
| Q4 2018 | $94,000 | -79.5% | 14,041 | -68.4% | 0.03% | -73.7% |
| Q3 2018 | $458,000 | +31.2% | 44,477 | -14.3% | 0.10% | +37.5% |
| Q2 2018 | $349,000 | – | 51,907 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |